Seldon Capital’s Novo Nordisk NVO Stock Holding History

Seldon Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,910	Closed	-$201K	–	74
2025 Q2	$201K	Hold	2,910	–	–	0.09%	65
2025 Q1	$202K	Hold	2,910	–	–	0.13%	56
2024 Q4	$250K	Hold	2,910	–	–	0.1%	56
2024 Q3	$346K	Hold	2,910	–	–	0.2%	46
2024 Q2	$415K	Hold	2,910	–	–	0.23%	37
2024 Q1	$374K	Hold	2,910	–	–	0.23%	40
2023 Q4	$301K	Hold	2,910	–	–	0.22%	40
2023 Q3	$265K	Hold	2,910	–	–	0.23%	42
2023 Q2	$235K	Sell	2,910 -2,910	-50%	-$238K	0.22%	48
2023 Q1	$463K	Buy	5,820 +2,910	+100%	+$206K	0.23%	43
2022 Q4	$197K	Hold	2,910	–	–	0.17%	44
2022 Q3	$145K	Hold	2,910	–	–	0.1%	55
2022 Q2	$162K	Hold	2,910	–	–	0.09%	57
2022 Q1	$162K	Hold	2,910	–	–	0.1%	63
2021 Q4	$163K	Buy	+2,910	New	+$158K	0.1%	75

Other funds holding NVO

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Seldon Capital's NVO Position: Q3 2025 in Review

Seldon Capital sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 2,910 shares — an estimated $201K sold.

Seldon Capital first reported a position in NVO in Q4 2021 and held it in 15 quarters. The position peaked at $463K in Q1 2023. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

Seldon Capital reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
Seldon Capital sold 2,910 Novo Nordisk shares in Q3 2025, an estimated $201K.
Seldon Capital first reported a position in Novo Nordisk in Q4 2021 and held it in 15 quarters.
Seldon Capital's Novo Nordisk position peaked at $463K in Q1 2023.
1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Seldon Capital's 13F filing for Q3 2025, filed 14 Nov 2025.